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5 regulated by the nuclear hormone receptor FXR (Apic et al., 2005) . These automated methods enable a more complete understanding of the complexity of these transcriptional factors (Ekins et al., 2002; Ulrich, 2003; Plant, 2004) . Ultimately the pathways generated rely on the quality of the content of the underlying database of literature interactions. These networks can also be used to overlay and explain experimental data from genomic and proteomic studies to further aid in analysis of this complex data. We are hence seeing a convergence of the different methods described above to create a field we have termed systems-ADME/TOX (Ekins et al., 2005d) .
We have built on the previously described efforts to generate networks of nuclear hormone interactions (Ekins et al., 2005c) as well as interpret microarray data for MCF-7 cells treated with 4-hydroxytamoxifen (OHT) and estrogen (Ekins et al., 2005c; Nikolsky et al., 2005) to develop and apply a novel method for systems-ADME/TOX (Ekins et al., 2005d) . This uses a subset of the MetaCore TM database, which is considerably enhanced with the previously described key drug metabolizing enzymes, their substrates, nuclear hormone receptors and other ADME/TOX related proteins to represent the backbone of the system termed MetaDrug TM . In addition we have used integrated human drug metabolism reactions (Korolev et al., 2003) and QSAR methods (Ekins et al., 2003; Balakin et al., 2004a; Balakin et al., 2004b) to enable the inference of potential interactions from an input molecular structure. These predicted interactions can also be visualized on networks alongside the empirical data and high throughput data (such as microarray) when available. As there are only a very limited number of molecules for which there is a complete published dataset for drug metabolism including characterization of the enzymes involved and microarray or other high throughput data, we were restricted to datasets with a combination of human or animal data which we recognize is far from ideal. However using mechanisms within both MetaDrug TM and MetaCore TM to map gene orthologs for different species we are able to visualize this data. This mixture of data types, sources and species also presents some difficulty for interpretation due to the differences in metabolism and toxicity between species, but there are presently few available alternatives available unless one has the resources available in a pharmaceutical company to generate such complete datasets. We have therefore analyzed recently published data from in vitro and microarray studies as test cases with this MetaDrug TM system. This preliminary study provides examples of how the integration of a database of ADME/Tox information, metabolism rules and QSAR methods may be used to generate predictions and analyze experimental microarray data relevant to drug disposition and toxicity.
Materials and Methods
Data annotation and software programming. The development of the underlying MetaCore TM and MetaDrug TM databases (GeneGo, St Joseph, MI) have been described in detail previously (Ekins et al., 2005b; Ekins et al., 2005c; Nikolsky et al., 2005) . For example, MetaDrug TM is an interactive, manually annotated database derived from literature publications on proteins and small molecules of relevance to drug disposition and toxicology in humans. MetaDrug TM was developed with an Oracle version 9.2.0.4 Standard Edition (Oracle, Redwood Shores, CA) based architecture for the representation of biological functionality and integration of functional, molecular, or clinical information (Bugrim et al., 2004 (Korolev et al., 2003) . These metabolic reactions now include many other phase I and II reactions that have been described elsewhere (Ekins et al., 2005a) . The prioritization of metabolites was achieved using a modified version of the method described previously (Boyer and Zamora, 2002 ) in which we have used the MetaDrug TM database to calculate the occurrence frequency of metabolites relating to the reaction rules. This occurrence frequency is then assigned as a negative log value to predicted molecules, the larger the score then the higher the frequency of similar metabolites observed in our database of literature metabolic information for humans. These rules were coded in a Perl script file used by the proprietary MetaDrug TM software. The panel of QSAR models (Ekins et al., 2005a) were generated using published data for various CYPs (Korolev et al., 2003) , transporters, ion channels and nuclear hormone receptors (Ekins and Swaan, 2004) gathered from many sources. This data was then used with a recursive partitioning tool ChemTree TM (GoldenHelix, Boseman, MT) (Young et al., 2002; Ekins et al., 2003) to generate the proprietary models stored in MetaDrug. The QSAR models were also validated by leaving groups out or using other external test sets. The correlation or Spearman's Rho value was then used as assessment criteria for model utilization. These QSAR models were integrated in MetaDrug TM , such that after sketching a molecule or selecting a file of structures, this could then be processed to generate metabolites and QSAR predictions as defined by the user. The similarity of the input molecules to those in the individual QSAR model training sets was calculated using the Tanimoto coefficient (Willet, 2003) using Accord software. The Tanimoto coefficient is: a /(a+b+c) were a= the number of bits common to both the query and target structures, b= the number of bits exclusively in the DMD #8458 8 query structure, c= the number of bits exclusively in the target structure. In this case a value of 1 indicates the molecule is identical to one in the training set. As this value decreases, the less similar the molecule is to molecules in the training set. The proteins in the MetaDrug database that relate to the specific QSAR models e.g. CYP3A4 were linked such that predictions could then be visualized as a network of interactions radiating from that protein. ChemTree TM was also integrated into MetaDrug TM to allow the user to generate QSAR models for integration within the software from their own data. MetaDrug TM and MetaCore TM can be freely evaluated by contacting GeneGo (www.genego.com).
Generation of metabolite and QSAR model predictions Molecules were either sketched in the
ChemDraw pluggin window or loaded from a mol or sdf file ( Figure 1 ). The molecules ( Figure 2 ) were then processed through the user defined metabolite rules and QSAR models developed with literature data (CYPs, P-gp, PXR etc) (Balakin et al., 2004a; Balakin et al., 2004b) . The user can specify which metabolic reaction rules and QSAR models are used as well as specify upper and lower prediction thresholds as a means to filter the molecules prior to visualizing on networks. The previously described network building algorithms (Ekins et al., 2005c) are used for visualizing the predicted interactions of metabolites or input molecules with the related proteins in MetaDrug
TM
. We were able to use the known molecules with metabolic pathways to test the software and predict interactions with these proteins as a network (Ekins et al., 2005a) .
Visualization of microarray data on gene networks in MetaDrug. We have previously described how data from microarray studies can be imported into MetaDrug TM on the client side as a tab-delimited file (Ekins et al., 2005c) . In this study we have used microarray data from livers of rats after treatment with L-742694 (structurally similar to Aprepitant) (Hartley et al., 2004) , human hepatocytes treated with Trovofloxacin (Liguori et al., 2005) and G 0 -arrested MCF-7 breast cancer cells treated with OHT (Hodges et al., 2003) . In addition we have visualized the TaqMan real time PCR data for human hepatocytes and DMD #8458
LS174T cells treated with Artemisinin (Burk et al., 2005) or other artemisinin analogs (Efferth and Oesch, 2004) . In most cases it is possible to extract the significant up / down regulated genes with the accession numbers from the pdf files of the publication (Hartley et al., 2004) The auto expand algorithm starts with a number of root nodes as specified by the user and builds sub-networks around every object from the uploaded set consisting of nearest neighbors. The expansion halts when the sub-networks intersect. The objects that do not contribute to connecting sub-networks are automatically truncated and there is no user control over the size of the network. Each connection represents a direct, experimentally confirmed, physical interaction between the objects. If a user is building a network around one node only the network generally consists of the nearest neighbors and their connections within 1-2 steps. The auto expand algorithm provides a means to look up one or more genes of interest and identify regulatory cascades that lead to or from the gene(s) of interest. These networks may become quite complex so it is likely that some filtering may be necessary to simplify the visualization.
Microarray data from rats are mapped onto the human networks using the gene ortholog information within MetaDrug TM . In some cases it was also possible to visualize predicted metabolite interactions with proteins and overlay the experimental expression data simultaneously. and takes a list of root nodes and for each node creates shortest paths networks to the other root nodes in the list and stops the network at a size defined by the user in the advanced options. This process is repeated iteratively until every node from the list is included in at least one network. The end-result of this is that it essentially fragments the "super-network" using the chosen nodes, down into sub-networks.
Each subnetwork is associated with a Z-score, G-score and p-value which rank the sub-networks according to saturation with the objects from the initial gene list. The Z-Score ranks the Analyze Network algorithm's sub-networks in regards to their saturation with genes from the experiment. A high Z-Score means the network is highly saturated with genes from the experiment. The G-Score combines the ZScore and the sum of the squares of the interactions to and from each of the nodes not related to the initial list. The value for the K coefficient can be specified in the advanced options section for the Analyze Network algorithm. The G-Score downgrades the Z-Score if there are high degree nodes that are not from the experiment in the sub-network. So, in general, a highly positive G-Score means the network is highly saturated with genes from the experiment and the network contains few to no high degree nodes not in the experiments; and a highly negative G-Score means there are many high degree nodes in the network that are not from the experiment. The p-Value is used to initially rank the sub-networks. The P-values throughout MetaCore -for maps, networks and processes are all calculated using the same basic formula:
a hypergeometric distribution where the p-value essentially represents the probability of particular mapping arising by chance, given the numbers of genes in the set of all genes on DMD #8458
11 maps/networks/processes, genes on a particular map/network/process and genes in the experiment. This function uses the same variables as the Z-Score. The equation for the Z-score, G-score and p value calculations is described below.
Where:
N -total number of nodes in MetaCore database R -number of the network's objects corresponding to the genes and proteins in your list n -total number of nodes in each small network generated from your list r -number of nodes with data in each small network generated from your list V i -number of links to/from i-th node {n/r} -denotes the set of nodes in a small network that are not related to user's list K -user-specified coefficient -used to "demote" networks with high-degree nodes that do not correspond to genes/proteins in user's list Gene-ontology processes are also mapped to the gene list and individual networks (see below).
The analyze networks algorithm is also used with raw data to present multiple pathways that may be statistically feasible for connecting the nodes from the input list with other nodes in the database via shortest pathways. The advantage of this network is that it may find a well connected cluster of root nodes without any predefined restrictions from the user and therefore presents more flexibility in the connections possible.
Results

Generation of metabolite and QSAR model predictions.
In the current study we have used the Ki (predicted, 8.1 µM; similarity score = 0.76) and interact with PXR (predicted to bind, probability = 0.58 similarity score = 0.77). MetaDrug produced 34 metabolites for Trovafloxacin including the major circulating metabolite Trovafloxacin glucuronide M1 (predicted log OC -0.9), acetylated Trovafloxacin M3 (-1.3) and Trovafloxacin sulphate M4 (predicted log OC -2.46). MetaDrug produced 28 metabolites for OHT including Endoxifen (predicted log OC -1) and 3,4-dihydroxytamoxifen (predicted log OC -0.97). OHT had a relatively high affinity for CYP3A4 K m (predicted, 55 µM; similarity score = 1), is also an inhibitor for P-gp (predicted, 15.1 µM; similarity score = 0.81), is further metabolized by phenol and estrogen sulfotransferases (SULT1A1K m model predicted 17.4 µM, similarity 1) and is an inducer of PXR (predicted to bind, probability 0.90, similarity score = 1). MetaDrug produced 17 metabolites for
Artemisinin including dihydroartemisinin (Log OC -5) and many hydroxylated metabolites (log OC -0.81). In addition predictions with various QSAR models indicated that CYP2B6 (13.4 µM, similarity 0.63), CYP3A4 (60.2 µM, similarity 0.7), PXR (predicted to bind, probability = 0.94 similarity 0.63), Pgp substrate (0.53, similarity 0.7), P-gp inhibitor (64.5 µM, similarity 0.7) were important.
Visualization of microarray data on gene networks in MetaDrug. Microarray data from rat livers after treatment with L-742694 was uploaded into MetaDrug and 17 out of 44 gene identifiers mapped in the database (Hartley et al., 2004) . These genes had been identified from a 25K rat microarray were a pvalue (< 0.01) and magnitude of regulation (log 10 ratio > 0.5) were considered significant (Hartley et al., 2004) . After generating a network this data was visualized alongside the predicted interactions derived were the p-value less than or equal to 0.01 was considered significant (Liguori et al., 2005) . In this case the microarray data does not appear to directly impact drug metabolism (data not shown). Microarray data from human MCF-7 cells treated with OHT (Hodges et al., 2003) was uploaded in to MetaDrug and 1446 out of 1617 gene identifiers mapped in the database (Supplemental Figure 1A ). This data was obtained raw from the microarray studies previously published (Hodges et al., 2003) . Both CYP3A4 and P-gp (MDR1) were up regulated in this dataset, indicating that this molecule may regulate its own transport and metabolism. TaqMan real time PCR data for human hepatocytes and LS174T cells treated with Artemisinin demonstrated induction of CYP3A4, CYP2B6 and MDR1 (Burk et al., 2005) . This small dataset of uploaded genes was uploaded after assigning LocusLink identifiers. 3 of 3 genes were accessible (Supplemental Figure 1B) . A second dataset used the NCI mRNA expression data in 60 cell lines after treatment with Artemisinin and related compounds (Efferth and Oesch, 2004) . These genes were selected from an initial list of 170 genes following cluster analysis into 3 groups using the complete linkage method, were mRNA expression correlated with cytotoxicity IC 50 data (Efferth and Oesch, 2004) .
The genes in cluster 1 and 2 were uploaded in MetaDrug and 28 of 36 genes mapped in the database some of which were present on the network of predicted interactions (Supplemental Figure 1C) .
Visualization of microarray data on gene networks in MetaCore. The same microarray datasets uploaded in MetaDrug TM previously, were evaluated in MetaCore TM with the analyze network algorithm.
The most statistically significant network based on the p-value (in parenthesis) as described above was generated in all cases. For L-742694 17 of 44 genes were uploaded and this gene list mapped onto the following GO processes using an approach similar to the EASE tool (Hosack et al., 2003) Figure 2B ). A network was generated from this gene list (Supplemental Figure 4A, Figure 4B ).
Discussion
The human physiology represents a complex system, therefore it is difficult when attempting to understand the changes in gene, protein or biological activity upon challenge with a drug (Nicholson et al., 2004 ). While we would not advocate that this is an impossible task to try to predict, there have been an increasing number of extensive toxicogenomics datasets that have been published from which we can learn. These studies have generally applied clustering methods to interpret the data. Example datasets for molecules evaluated in this way either in vivo in animal species, isolated cells or cell lines are accumulating, resulting in the need for accessible databases and tools for expedited analysis, data mining and hypothesis generation. The MetaDrug TM database uses a novel architecture described previously (Ekins et al., 2005c) , allowing the organization and visualization of biological and chemical information.
This approach generates networks which are more informative than linear pathways as commonly described in biology text books. We have applied this database platform previously to visualize the nuclear hormone receptor interactions, providing a qualitative understanding of the current state of knowledge (Ekins et al., 2005c) . We have used a second platform MetaCore which includes more network building algorithms to visualize microarray data for MCF-7 cells treated with OHT and estrogen for 24h (Hodges et al., 2003) . This enabled us to generate, compare and subtract networks to produce signature gene-networks for each molecule (Nikolsky et al., 2005 ).
In the current study we have extended the MetaDrug platform beyond a database of ADME/TOX related content to further include a rule based method to generate predicted metabolites (Korolev et al., 2003) and QSAR methods for predicting interactions with ADME/TOX related proteins (Balakin et al., 2004a; Balakin et al., 2004b; Ekins and Swaan, 2004) as well as other physicochemical properties (Ekins et al., 2005a) . Recent testing of MetaDrug with 66 molecules (Supplemental Table 2 , available online)
indicates we capture at least 78.8 % (on average) of correctly predicted first pass metabolites. Much earlier testing on 28 of these molecules indicated approximately 73 % of metabolites were correctly identified (Ekins et al., 2005a) . However there is still room for future improvement to minimize the number of total metabolites predicted, as well as the addition of further rules for metabolic reaction not currently captured (e.g. conjugation at the selenium atom in Ebselen). The metabolism predictions for Aprepitant, L-742694, Trovofloxacin, 4-hydroxytamoxifen and artemisinin and artemisinin, outlined earlier included the prediction of phase II metabolites. MetaDrug therefore represents a systems-ADME/TOX platform for the prediction of metabolism and interactions from molecular structure as well as the visualization and simultaneous analysis of multiple high throughput data types (such as microarrays) (Ekins et al., 2005d) . As such, the approach is highly novel, integrating not only different algorithms for predictions but also data parsers, algorithms for network generation, visualization tools and data filters. This latter component enables the selection of genes associated with a specific species, tissue or organelle, for example.
To demonstrate the utility of such a platform we have analyzed several recently published datasets from in vitro and/or microarray studies for Aprepitant (Sanchez et al., 2004) , L-742694 (Hartley et al., 2004) , Trovofloxacin (Dalvie et al., 1997; Liguori et al., 2005) , OHT (Crewe et al., 1997; Chen et al., 2002; Desai et al., 2002; Hodges et al., 2003; Bekaii-Saab et al., 2004; Desta et al., 2004) and Artemisinin (Svensson and Ashton, 1999; Svensson et al., 2003; Efferth and Oesch, 2004; Burk et al., 2005) . In all cases the data was taken from the papers following clustering or other statistical pre-analysis. However we have previously described the analysis of 'raw' microarray data without the need for clustering or other similar approaches (Nikolsky et al., 2005) . We have used the molecular structure of the test molecules described above with MetaDrug generated metabolites, predictions for affinity to multiple ADME/TOX related proteins and auto-expand gene-networks of these predicted protein interactions alongside available microarray data. These gene networks were compared with an analysis performed
with MetaCore TM using the analyze network algorithm with all available microarray data for each compound after the clustering performed in the published papers. OHT was predicted to bind to PXR and once again was indicated to be present in the training set (Desai et al., 2002) . Binding to PXR would be expected to increase levels of CYP3A4 that is in turn involved in OHT formation from Tamoxifen (Crewe et al., 1997) . Microarray data from human MCF-7 cells treated with OHT was uploaded and was mapped in the MetaDrug database (Supplemental Figure 1A) . Both CYP3A4 and P-gp (MDR1) were up-regulated in this dataset, once again indicating that this molecule may regulate its own transport and metabolism. MetaDrug TM produced 17 metabolites for Artemisinin including one of the known metabolites observed in human plasma, namely dihydroartemisinin (Svensson and Ashton, 1999) . Little else is known regarding the human in vitro metabolism of this compound. It is possible that CYP2B6 could be responsible for forming this metabolite as this occurs in the same location DMD #8458 20 as the O-deethylation of β-arteether (Grace et al., 1998) which is mediated by the same enzyme. The hydroxylation of artemisinin may also be mediated by CYP2B6 which is known to be involved in numerous metabolic reactions (Ekins and Wrighton, 1999) . In addition, predictions with the various QSAR models indicated that artemisinin binds CYP2B6, CYP3A4, PXR, and is unlikely to be a P-gp substrate (but is a weak P-gp Inhibitor). These predictions are in very good agreement with the metabolism data (Svensson and Ashton, 1999; Li et al., 2003) while recent studies suggested artemisinin binds PXR with an EC 50 of 34 µM and inhibits P-gp mediated digoxin transport with an IC 50 of 33 µM (Burk et al., 2005) . This same study generated PCR data with human hepatocytes treated with artemisinin to show the induction of CYP3A4, CYP2B6 and P-gp (Burk et al., 2005) . The gene expression data can be visualized alongside the predicted interactions to show the other transcriptional regulators of these proteins (Supplemental Figure 1B) . A second data set derived from the NCI cell lines treated with artemisinin analogs and clustered (Efferth and Oesch, 2004) was also overlapped on the same network (Supplemental Figure 1C) .
In 3 of the 4 cases presented we were able to visualize gene expression data alongside the predicted interactions in MD using the autoexpand algorithm. Using a second platform MetaCore, we were able to use a different network building algorithm, namely 'analyze network' which provides multiple significant small scale networks with statistical significance and enables the mapping of Gene Ontology data. The network with the most significant p-value was then generated in all cases. These networks do not allow the user to generate predicted molecules on the networks as in MetaDrug TM , but they do provide considerable insight into the significance of the gene expression data. The L-742694 gene expression data set from rat liver was mapped on the human orthologs in MetaCore TM and indicated a significant link with metabolism ( Figure 4A, B) as the data mapped to the metabolism based GO processes. This corresponds with the observation that L-742694 impacts the PXR responsive gene battery and the structurally similar Aprepitant is metabolized by CYP3A4 as well as other CYPs (Hartley et al., 2004; Sanchez et al., 2004) . The Trovafloxacin dataset, was linked with many GO processes from signal transduction to protein transport likely to be involved as part of an oxidative stress response (Supplemental Figure 2A ,B) which perhaps strengthens the observations made after clustering the human hepatocyte gene expression data (Liguori et al., 2005) . The OHT dataset mapped onto the GO processes related to the cell cycle (Supplemental Figure 3 ) which corresponds well with the microarray data from MCF-7 cells (Hodges et al., 2003) . The Artmesinin analog microarray dataset was linked to metabolism, cell cycle and oxidative stress GO processes (Supplemental Figure 4) correlating well with the observations of cytotoxicity observed from clustering the NCI cell line data (Efferth and Oesch, 2004) , and metabolism in human cells (Burk et al., 2005) . The ability to highlight the genes involved with each GO process on the networks is a valuable approach for quickly identifying their position and relationships with other genes on the network. It is important to note that although we are able to map a large number of the genes uploaded into the software either directly or using DAVID, there will be future improvements in the database or using different identifiers instead of LocusLink (e.g. HomoloGene), which will enable more genes to be visualized. Another important consideration is the potential for species differences in receptor binding, metabolism and toxicity. One example we have used previously as an example to illustrate the utility of building species specific gene networks is the drug pyrazinamide.
This blocks NAD+ metabolism to result in the accumulation of the toxic uric acid metabolite in humans but not mice (Bugrim et al., 2004) . We have also previously indicated how MetaDrug can be used to simulate the effect of knock out or inhibition of a target gene, by simply removing it from a network. This would then open the possibility to allow the user to consider species differences or different genotypes.
From these test cases it is apparent that although we can suggest the majority of the major metabolites for these compounds we either do not identify some others or predict metabolites that have not been identified to date. This will need to be rectified in future by allowing the user to add their own reaction rules to the software to generate metabolites currently missing. Over prediction will require the development of a machine learning algorithm based on the available human metabolism data or an expansion of the rules for metabolic pathways using reasoning (Button et al., 2003) or alternative approaches. The availability of multiple QSAR models for particular ADME properties is currently limited to published literature available to us. The capability to generate QSAR models with the software included in MetaDrug TM (not discussed here), will allow the user to incorporate their own data for ADME/Tox properties or therapeutic targets whether based around a single or multiple structural series.
There is considerable flexibility in the user being able to add their own biological data (e. 
